Table 1.
The activity of non-antibiotics (active substances and medicinal products) with and without the efflux pump inhibitor PAβN against standard Gram-negative strains.
| Strains | MIC (mg/L) | ||||
|---|---|---|---|---|---|
| alen/Ostenil a
(+PAβN) b |
tic/Apo-Clodin a
(+PAβN)b |
amit/Amitriptylinum a
(+PAβN)b |
nic/Niglostin a
(+PAβN)b |
crb/Carbosin a
(+PAβN)b |
|
| E. coli ATCC 25922 | >800 (200/100) | >800 (25) | 200 (50) | >800 (100) | >800 (>800) |
| E. coli NCTC 8196 | >800 (200/100) | >800 (25) | 200 (50) | >800 (100) | >800 (>800) |
| E. coli NCTC 10538 | >800 (200/100) | >800 (25) | 400 (25) | >800 (100) | >800 (>800) |
| K. pneumoniae ATCC 13883 | >800 (200) | >800 (25) | 200 (50) | >800 (200) | >800 (>800) |
| K. pneumoniae ATCC 700603 | >800 (800) | >800 (100) | 400 (100) | >800 (>800) | >800 (>800) |
| P. vulgaris ATCC 13315 | >800 (400) | >800 (>800) | 800 (800) | >800 (>800) | >800 (>800) |
| P. aeruginosa ATCC 27853 | 200 (25) | >800 (>800) | 800 (25) | >800 (>800) | 800 (200) |
| P. aeruginosa NCTC 6749 | 100 (25) | >800 (>800) | 800 (400) | >800 (>800) | 800 (400) |
| P. aeruginosa PAO1 | 100 (25) | >800 (>800) | 800 (400) | >800 (>800) | 800 (400) |
| S. maltophilia ATCC 13637 | 200 (100) | >800 (12.5/25) | 100 (50) | >800 (800) | >800 (>800) |
| S. maltophilia ATCC 12714 | 400 (400) | >800 (50) | 200 (100) | >800 (800) | >800 (>800) |
| A. baumannii ATCC 19606 | >800 (800) | >800 (400) | 200 (50) | >800 (100) | >800 (>800) |
| B. cepacia ATCC 25416 | >800 (800) | >800 (>800) | 800 (800) | >800 (>800) | 800 (800) |
alen, alendronate sodium; tic, ticlopidine; amit, amitriptyline; nic, nicergoline; crb, carboplatin; PAβN, Phe-Arg-β-naphthylamide. a When a difference between the minimum inhibitory concentration (MIC) values of the non-antibiotic active substance and medicinal product with and without PAβN was observed, both minimum inhibitory concentrations (MICs) of the active substance and its medicinal product are presented; b At least 4-fold decrease in the MIC of non-antibiotic active substances and medicinal products in the presence of PAβN, when compared with the MIC values of non-antibiotics without PAβN, is indicated in boldface.